Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trialSiri Lillegraven, Nina Paulshus Sundlisæter, Anna-Birgitte Aga, Joseph Sexton, Inge Christoffer Olsen, Åse Stavland Lexberg, Tor Magne Madland, Hallvard Fremstad, Christian A. Høili, Gunnstein Bakland, Cristina Spada, Hilde Haukeland, Inger Myrnes Hansen, Ellen Moholt, Till UhligSee the full list of authors
22 August 2023
Cost–utility analysis of tapering strategies of biologicals in rheumatoid arthritis patients in the NetherlandsLuuk van Esveld, Juul M Cox, T Martijn Kuijper, Tessa M Bosch, Angelique EAM Weel-Koenders
9 July 2023
Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trialMikkel Østergaard, Ronald F van Vollenhoven, Anna Rudin, Merete Lund Hetland, Marte Schrumpf Heiberg, Dan C Nordström, Michael T Nurmohamed, Bjorn Gudbjornsson, Lykke Midtbøll Ørnbjerg, Pernille Bøyesen, Kristina Lend, Kim Hørslev-Petersen, Till Uhlig, Tuulikki Sokka, Gerdur GrondalSee the full list of authors
9 July 2023
Three-month tapering and discontinuation of long- term, low-dose glucocorticoids in senior patients with rheumatoid arthritis is feasible and safe: placebo-controlled double blind tapering after the GLORIA trialAbdullah Ali Hadi Almayali, Maarten Boers, Linda Hartman, Daniela Opris, Reinhard Bos, Marc R Kok, Jose AP Da Silva, Ed Griep, Ruth Klaasen, Cornelia F Allaart, Paul Baudoin, Hennie G Raterman, Zoltan Szekanecz, Frank Buttgereit, Pavol MasarykSee the full list of authors
4 August 2023
Extracellular aaRSs drive autoimmune and inflammatory responses in rheumatoid arthritis via the release of cytokines and PAD4Akihiro Kimura, Takeshi Takagi, Thiprampai Thamamongood, Satoshi Sakamoto, Takumi Ito, Iwao Seki, Masahiro Okamoto, Hiroyuki Aono, Satoshi Serada, Tetsuji Naka, Hiroaki Imataka, Kensuke Miyake, Takuya Ueda, Miki Miyanokoshi, Keisuke WakasugiSee the full list of authors
2 July 2023
Safety profile of upadacitinib in patients at risk of cardiovascular disease: integrated post hoc analysis of the SELECT phase III rheumatoid arthritis clinical programmeRoy Fleischmann, Jeffrey R Curtis, Christina Charles-Schoeman, Eduardo Mysler, Kunihiro Yamaoka, Christophe Richez, Hannah Palac, Deanne Dilley, Jianzhong Liu, Sander Strengholt, Gerd Burmester
12 June 2023
Cytokine-directed cellular cross-talk imprints synovial pathotypes in rheumatoid arthritisMaximilian Kugler, Mirjam Dellinger, Felix Kartnig, Lena Müller, Teresa Preglej, Leonhard X Heinz, Elisabeth Simader, Lisa Göschl, Stephan E Puchner, Sebastian Weiss, Lisa E Shaw, Matthias Farlik, Wolfgang Weninger, Giulio Superti-Furga, Josef S SmolenSee the full list of authors
21 June 2023
Irreversible covalent Bruton’s tyrosine kinase inhibitor, TAS5315 versus placebo in rheumatoid arthritis patients with inadequate response to methotrexate: a randomised, double-blind, phase IIa trialTsutomu Takeuchi, Sakae Tanaka, Mitsuru Murata, Yoshiya Tanaka
22 May 2023
Identification of MYH9 as a key regulator for synoviocyte migration and invasion through secretome profilingSaseong Lee, Eunbyeol Choi, Sehyun Chae, Jung Hee Koh, Yoolim Choi, Jung Gon Kim, Seung-Ah Yoo, Daehee Hwang, Wan-Uk Kim
15 May 2023
Country-level socioeconomic status relates geographical latitude to the onset of RA: a worldwide cross-sectional analysis in the METEOR registrySytske Anne Bergstra, Alexandre Sepriano, Arvind Chopra, Lai-Ling Winchow, David Vega-Morales, Karen Salomon-Escoto, Xanthe M E Matthijssen, Robert BM Landewé
25 May 2023
